First National Trust Co Boosts Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

First National Trust Co grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,127 shares of the medical equipment provider’s stock after acquiring an additional 115 shares during the period. First National Trust Co’s holdings in Intuitive Surgical were worth $1,055,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. J.W. Cole Advisors Inc. lifted its stake in shares of Intuitive Surgical by 8.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 2,040 shares of the medical equipment provider’s stock valued at $596,000 after purchasing an additional 156 shares during the period. Sage Mountain Advisors LLC increased its holdings in Intuitive Surgical by 7.7% in the third quarter. Sage Mountain Advisors LLC now owns 1,253 shares of the medical equipment provider’s stock valued at $366,000 after buying an additional 90 shares in the last quarter. Everhart Financial Group Inc. raised its position in shares of Intuitive Surgical by 15.6% in the third quarter. Everhart Financial Group Inc. now owns 1,450 shares of the medical equipment provider’s stock worth $424,000 after acquiring an additional 196 shares during the period. Pinnacle Wealth Management Advisory Group LLC grew its position in shares of Intuitive Surgical by 6.4% during the 3rd quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,479 shares of the medical equipment provider’s stock valued at $432,000 after acquiring an additional 89 shares during the period. Finally, Brighton Jones LLC increased its stake in shares of Intuitive Surgical by 0.9% in the 3rd quarter. Brighton Jones LLC now owns 8,881 shares of the medical equipment provider’s stock valued at $2,596,000 after purchasing an additional 79 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ISRG. Wells Fargo & Company increased their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Raymond James boosted their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Finally, Citigroup boosted their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Stock Up 1.0 %

NASDAQ:ISRG traded up $3.71 on Friday, hitting $381.36. The stock had a trading volume of 1,028,858 shares, compared to its average volume of 1,492,254. The stock has a market cap of $135.27 billion, a price-to-earnings ratio of 68.84, a PEG ratio of 4.93 and a beta of 1.39. The company has a fifty day moving average price of $385.40 and a two-hundred day moving average price of $349.30. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.00 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Buying and Selling

In related news, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the sale, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the transaction, the president now owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The disclosure for this sale can be found here. Insiders have sold a total of 226,928 shares of company stock valued at $87,833,828 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.